According to a new study, the drug Tamoxifen can be given to women who are at risk for breast cancer to reduce cancer deaths and save money.
As per the results of a new mathematical model, the Tamoxifen drug can prevent 29 breast cancer cases and nine breast cancer deaths in every 100 women that get treated by it. Aside from those staggering figures, the most impressive thing about this drug is its low cost. For every 1,000 women that were treated, Tamoxifen would save $47,580, according to researchers.
The downside to the drug, though, is the very serious side-effects that may accompany usage. It increases the odds of getting a stroke, endometrial cancer, onset of menopause and/or hot flashes in post-menopausal women.
Despite the possible ramifications, the FDA has approved this drug. As such, it will soon be available to the general public when treatment for cancer is necessary.
"There's a group of women who potentially could benefit from taking Tamoxifen," said study researcher Dr. Peter Alperin, of Archimedes Inc. in San Francisco, a company that creates computer models to answer questions related to health care. "These women should definitely talk with their physicians to understand what it means for them."
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...